
1. vaccine. 2012 jan 20;30(5):904-10. doi: 10.1016/j.vaccine.2011.11.096. epub 2011 
dec 7.

safety, tolerability, immunogenicity 1 2 doses zoster vaccine in
healthy adults ≥60 years age.

vermeulen jn(1), lange jm, tyring sk, peters ph, nunez m, poland g, levin mj,
freeman c, chalikonda i, li j, smith jg, caulfield mj, stek je, chan is, vessey
r, schödel fp, annunziato pw, schlienger k, silber jl.

author information: 
(1)academic medical center, university amsterdam, amsterdam, netherlands.

background: incidence severity herpes zoster (hz) postherpetic
neuralgia increase age, associated age-related decrease immunity 
varicella-zoster virus (vzv). one dose zoster vaccine (zv) demonstrated
substantial protection hz; study examined impact second dose of
zv.
methods: randomized, double-blind, multicenter study 210 subjects ≥60 years 
old compared immunity safety profiles one two doses zv,
separated 6 weeks, vs. placebo. immunogenicity evaluated using vzv
interferon-gamma (ifn-γ) enzyme-linked immunospot (elispot) assay vzv
glycoprotein enzyme-linked immunosorbent antibody (gpelisa) assay. adverse
experiences (aes) recorded standardized vaccination report card.
results: serious vaccine-related aes occurred. vzv ifn-γ elispot geometric
mean count (gmc) spot-forming cells per 10(6) peripheral blood mononuclear
cells increased zv group 16.9 prevaccination 49.5 32.8 2
and 6 weeks postdose 1, respectively. two weeks, 6 weeks 6 months postdose 2,
gmc 44.3, 42.9, 36.5, respectively. gmc placebo group not
change study. peak elispot response occurred ∼2 weeks each
zv dose. gpelisa geometric mean titers (gmts) zv group higher
than placebo group 6 weeks dose. correlation the
ifn-γ elispot gpelisa assays poor.
conclusions: zv generally well-tolerated immunogenic adults ≥60 years 
old. second dose zv generally safe, boost vzv-specific
immunity beyond levels achieved postdose 1.

copyright © 2011 elsevier ltd. rights reserved.

doi: 10.1016/j.vaccine.2011.11.096 
pmid: 22154769  [indexed medline]

